Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
QNova Capital is a venture capital firm founded to support biotech and medtech founders. Based in the United States, the firm focuses on accelerating innovation and growth in the life sciences sector. QNova Capital leverages deep regulatory and clinical expertise to facilitate liquidity for investors and has a history of successful drug and device approvals.
Backed by QNova LifeSciences, a clinical research and regulatory organization with over 30 years of experience, QNova Capital integrates its resources with capital deployment to provide a comprehensive support model for startups. The firm has been instrumental in helping portfolio companies raise over $700 million in the past three years. Although specific founding year details are not disclosed, QNova Capital has established itself as a key player in the biotech and medtech investment space.
QNova Capital invests in medical devices, therapeutics, and diagnostics, particularly in oncology, infectious disease, metabolic health, and personal health. The firm emphasizes Class 2 devices and aims to mitigate the time, cost, and risk associated with FDA approval processes. Their investment strategy is informed by extensive experience in regulatory strategy, product development, and venture investing.
Investing at the seed, Series A, and Series B stages, QNova Capital seeks founders with deep domain expertise and regulatory experience. The firm focuses on novel assets with global sourcing potential, integrating its CRO resources with capital deployment to enhance the support provided to portfolio companies. This approach allows QNova Capital to navigate the complexities of FDA approvals effectively, making it a valuable partner for startups in the life sciences sector.
Jim Sergi, MSN - Partner. Jim is a biotech innovator and investor with extensive regulatory expertise. He has a proven track record of over 85 NDA/BLA approvals and 250 medical device clearances. He is also the Founder and President of CSSi LifeSciences.
John Stanton - Partner. John is a seasoned venture investor and operator with experience across high-tech, biotech, and medtech early-stage startups. He co-founded SVG Ventures and brings a wealth of knowledge to QNova Capital.
Richard Moran, Ph.D. - Partner. Richard has a strong background in regulatory strategy and product development, contributing to QNova's focus on navigating FDA approval processes.
John Gustin, PhD, MBA - Vice President, Operations. John oversees operational aspects at QNova Capital, ensuring that the firm effectively supports its portfolio companies.
To pitch QNova Capital, founders should use the contact form available on their website at qnova.capital. It is essential to include a comprehensive pitch deck that outlines the startup's regulatory strategy, market potential, and clinical development plans. Founders should expect a response within a few weeks, and warm introductions are preferred but not mandatory.
QNova Capital runs the QNova Accelerator, a medtech acceleration program designed to support startups in funding, FDA strategy, and go-to-market efforts. This program provides participants with access to resources and expertise necessary for navigating the complexities of the biotech landscape.
Eligibility for the QNova Accelerator typically includes early-stage medtech companies seeking guidance on regulatory processes and commercialization strategies. Interested startups can apply through the QNova LifeSciences website for more details.
In recent developments, QNova Capital has formed a strategic alliance with Phase Advance to advance AI-driven, non-animal drug development. This partnership aims to enhance the drug development process by integrating innovative technologies.
Additionally, QNova LifeSciences, the clinical research organization backing QNova Capital, has successfully helped portfolio and client companies raise over $700 million in the past three years, showcasing the firm's effectiveness in supporting biotech and medtech ventures.
What are QNova Capital's investment criteria?
QNova Capital focuses on biotech and medtech startups, particularly in medical devices, therapeutics, and diagnostics. They emphasize investments in oncology, infectious disease, metabolic health, and personal health, specifically targeting Class 2 medical devices.
How can founders apply or pitch to QNova Capital?
Founders can pitch to QNova Capital through their website at qnova.capital. It is advisable to include detailed information about the startup's regulatory strategy and clinical development plans in the pitch deck.
What makes QNova Capital different from other venture firms?
QNova Capital differentiates itself through its deep regulatory expertise and a proven track record of successful drug and device approvals. The firm integrates its clinical research organization resources with capital deployment, providing a comprehensive support model for biotech and medtech startups.
What is QNova Capital's geographic scope?
While QNova Capital is based in the United States, it engages in global deal sourcing, allowing it to identify promising investment opportunities worldwide.
What kind of post-investment involvement does QNova Capital have?
QNova Capital provides extensive post-investment support, including fundraising guidance, FDA strategy assistance, and US commercialization support, leveraging its network and expertise to help portfolio companies succeed.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.